Posted on 895
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical program for Avigan, spanning the spectrum of Asymptomatic to severe cases of COVID in both outpatient and in-patient setting. The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr. Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue.
Dr Reddy’s, GRA terminate Avigan study on hospitalised Covid cases in Kuwait
January 27, 2021
× Dr Reddy’s Laboratories Ltd and Global Response Aid FZCO (GRA) on Wednesday announced the termination of an Avigan Trial Study conducted in Kuwait focussed on moderate to severe Covid patients in a hospital setting.
The hospitalised patient study was one of the studies in the overall clinical programme for Avigan, spanning the spectrum of asymptomatic to severe cases of Covid in both outpatient and in-patient settings. Avigan is a trademark of Fujifilm Toyama Chemical Co Ltd.
The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue.
Dr Reddy s terminates Avigan trial study in Kuwait daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.
Dr Reddy s Laboratories on Wednesday announced termination of Avigan trial study being conducted in Kuwait that was focused on moderate to severe COVID-19 patients in a hospital setting. It was one of the studies in the overall clinical programme for Fujifilm s Avigan, an antiviral medication, spanning the spectrum of asymptomatic to severe cases of COVID-19 in both outpatient and inpatient setting, the drug major said in a statement. The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by the company in partnership with Appili Therapuetics and Global Response Aid, shall continue, it added.